RxDoctor Payments Data

Yedy Hernandez

Family · Hialeah, FLNPI 1750951778

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 49 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$213
  • Lilly USA, LLC$210
  • Exact Sciences$141
  • AstraZeneca$89
  • AbbVie$65
  • GSK$63
  • plus $300 from 11 others

What the payments were for

  • Food & beverage$1,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$3,670
Medicare patients
53
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$44,340
JardianceEmpagliflozin25$36,196
VascepaIcosapent Ethyl41$32,736
LinzessLinaclotide24$23,154
JanuviaSitagliptin Phosphate16$18,978
OzempicSemaglutide17$16,162
TrulicityDulaglutide11$12,748
SynthroidLevothyroxine Sodium30$4,203
Breo ElliptaFluticasone/Vilanterol12$3,450
Omeprazole103$1,875
Diclofenac Sodium52$1,725
Atorvastatin Calcium214$1,224
Rosuvastatin Calcium117$1,144
Losartan Potassium148$962
Fluticasone Propionate76$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$89$44,34034 claims
AbbVieLinzess, Synthroid$65$27,35754 claims
Novo NordiskOzempic$213$16,16217 claims
Lilly USA, LLCTrulicity$210$12,74811 claims
GSKBreo Ellipta$63$3,45012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →